Your browser doesn't support javascript.
loading
Predictive value of retinal atrophy for cognitive decline across disease duration in multiple sclerosis.
Alba-Arbalat, Salut; Solana, Elisabeth; Lopez-Soley, Elisabet; Camos-Carreras, Anna; Martinez-Heras, Eloy; Vivó, Francesc; Pulido-Valdeolivas, Irene; Andorra, Magi; Sepulveda, Maria; Cabrera, Jose María; Fonseca, Elianet; Calvi, Alberto; Alcubierre, Rafel; Dotti-Boada, Marina; Saiz, Albert; Martinez-Lapiscina, Elena H; Villoslada, Pablo; Blanco, Yolanda; Sanchez-Dalmau, Bernardo; Llufriu, Sara.
Afiliação
  • Alba-Arbalat S; Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Solana E; Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain.
  • Lopez-Soley E; Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Camos-Carreras A; Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain.
  • Martinez-Heras E; Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Vivó F; Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain.
  • Pulido-Valdeolivas I; Ophthalmology Department, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Andorra M; Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Sepulveda M; Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain.
  • Cabrera JM; Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Fonseca E; Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain.
  • Calvi A; Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain.
  • Alcubierre R; Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain.
  • Dotti-Boada M; Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Saiz A; Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain.
  • Martinez-Lapiscina EH; Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Villoslada P; Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain.
  • Blanco Y; Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain.
  • Sanchez-Dalmau B; Neurology Department, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Llufriu S; Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain.
J Neurol Neurosurg Psychiatry ; 95(5): 419-425, 2024 Apr 12.
Article em En | MEDLINE | ID: mdl-37989566
ABSTRACT

BACKGROUND:

We investigated the association between changes in retinal thickness and cognition in people with MS (PwMS), exploring the predictive value of optical coherence tomography (OCT) markers of neuroaxonal damage for global cognitive decline at different periods of disease.

METHOD:

We quantified the peripapillary retinal nerve fibre (pRFNL) and ganglion cell-inner plexiform (GCIPL) layers thicknesses of 207 PwMS and performed neuropsychological evaluations. The cohort was divided based on disease duration (≤5 years or >5 years). We studied associations between changes in OCT and cognition over time, and assessed the risk of cognitive decline of a pRFNL≤88 µm or GCIPL≤77 µm and its predictive value.

RESULTS:

Changes in pRFNL and GCIPL thickness over 3.2 years were associated with evolution of cognitive scores, in the entire cohort and in patients with more than 5 years of disease (p<0.01). Changes in cognition were related to less use of disease-modifying drugs, but not OCT metrics in PwMS within 5 years of onset. A pRFNL≤88 µm was associated with earlier cognitive disability (3.7 vs 9.9 years) and higher risk of cognitive deterioration (HR=1.64, p=0.022). A GCIPL≤77 µm was not associated with a higher risk of cognitive decline, but a trend was observed at ≤91.5 µm in PwMS with longer disease (HR=1.81, p=0.061).

CONCLUSIONS:

The progressive retinal thinning is related to cognitive decline, indicating that cognitive dysfunction is a late manifestation of accumulated neuroaxonal damage. Quantifying the pRFNL aids in identifying individuals at risk of cognitive dysfunction.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Disfunção Cognitiva / Esclerose Múltipla Limite: Humans Idioma: En Revista: J Neurol Neurosurg Psychiatry Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Disfunção Cognitiva / Esclerose Múltipla Limite: Humans Idioma: En Revista: J Neurol Neurosurg Psychiatry Ano de publicação: 2024 Tipo de documento: Article